Latest news with #BioLabHoldings
Malaysian Reserve
31-07-2025
- Health
- Malaysian Reserve
BioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products
Study Will Compare Four Amnion-Based Therapies Plus Standard of Care to Standard of Care Alone in Chronic Wound Management PHOENIX, July 31, 2025 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in regenerative wound care, has initiated its most comprehensive clinical trial to date. The multicenter, prospective, randomized controlled study will evaluate the efficacy of four human placental membrane (HPM) products in combination with standard of care (SOC) compared to SOC alone in the treatment of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The trial, formally titled 'A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP),' will enroll 650 subjects across up to 30 clinical sites nationwide. 'This study represents a major milestone in our commitment to advancing wound care through rigorous clinical research,' said Dr. Marshall Medley, chief medical officer at BioLab. 'By evaluating our full suite of amnion-based products in a real-world setting, we aim to provide clinicians with robust data to guide treatment decisions for patients with chronic wounds.' Participants will be randomized to receive one of four BioLab products—Tri-Membrane Wrap™ (HPM-1), Membrane Wrap™ (HPM-2), Membrane Wrap-Lite™ (HPM-3), or Membrane Wrap-Hydro™ (HPM-4)—in addition to SOC, or SOC alone. Treatments will be applied weekly for up to 12 weeks or until complete wound closure is achieved and confirmed two weeks later. Optional weekly visits will allow for dressing changes in both study arms. The study is designed to capture real-world clinical outcomes and support the growing body of evidence for the use of placental-derived allografts in chronic wound management. For more information on BioLab Holdings, Inc. and its regenerative wound care solutions, visit About BioLab Holdings, Holdings, Inc. is a Phoenix-based medical manufacturer focused on wound healing and regenerative medicine. Its product portfolio includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™ and Membrane Wrap – Hydro™, all derived from human amniotic membrane. These minimally manipulated allografts are designed to preserve the tissue's natural properties and support healing. BioLab is committed to delivering safe, high-quality products through innovation, education and exceptional customer service. Learn more at Contact: Kwyn LowePhone: 406.314.5120Email: kwyn@
Yahoo
07-03-2025
- Business
- Yahoo
BioLab Holdings, Inc. Announces Partnership with Real Collagen GmbH
Investment and Partnership will Allow Manufacturer to Create New Wound Care Products Using Fish Collagen PHOENIX, March 7, 2025 /PRNewswire/ -- BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in wound healing and wound care products, is proud to announce its partnership and collaboration agreement with Real Collagen GmbH, a German biotechnology company specializing in the manufacturing of fish collagen for treating medical conditions including chronic wounds. Through this partnership, BioLab will develop new, novel products, initially in the wound healing space, with the goal to better address patient needs and augment and expand its portfolio of wound care offerings. Real Collagen GmbH possesses over 15 years of experience developing and producing raw hydrogel material containing fish collagen. Its unique method of obtaining collagen, combined with high-quality fish skin, results in collagen material with valuable properties. The raw product is primed to provide universal, high-quality, and effective wound dressing and aims to offer an affordable product for various wound types. During production of the collagen, a catalyzed hydration process is used to obtain native tropocollagen from fish skin, preserving its triple helix structure and properties. Fish skin, chosen for its safety, antimicrobial, anti-inflammatory, and analgesic properties, is used as a raw material. The resulting collagen is pure and stable. The material is suitable for many wound types, patients, and is easy to apply. "Through this agreement with Real Collagen, we establish a partnership for the development of novel products with a group that shares our values and vision, but most importantly our passion for patient care," said Dr. Carlos Encinas, chief science officer at BioLab. "Biolab Holding's investment into Real Collagen signifies our continued commitment to helping patients heal from chronic and acute wounds," said BioLab President Jaime Leija. "We understand the importance of providing valuable resources to medical providers across the world and intend to leverage the collagen produced by Real Collagen in a multitude of wound care solutions, including our proprietary technology, Dermistat." "At Real Collagen, we are dedicated to producing high-quality raw fish collagen and we're proud to partner with BioLab Holdings, Inc.," said Real Collagen CEO Dr. Jan Lorenz. "By combining our expertise in fish collagen technology with BioLab's commitment to patient-centered products, we are confident that this collaboration will lead to groundbreaking advancements in wound healing. Together, we strive to provide medical professionals with superior solutions to improve patient outcomes worldwide." BioLab looks forward to providing additional updates on the wound products made in partnership with Real Collagen. For more information on BioLab Holdings, Inc., visit About BioLab Holdings, Holdings, Inc. is a Phoenix-based medical manufacturer specializing in wound healing. Its products, Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™, and Membrane Wrap - Hydro™, use human tissue allograft derived from amniotic membrane that provides structural tissue for use as a wound protectant covering. The products are minimally manipulated, preserving the properties that the tissue exhibits in its natural state. The company's mission is to manufacture reliable and safe products with the highest quality to help optimize body performance through continuous innovation, education, superior customer service and teamwork. For more information, visit Contact: Kwyn LowePhone: 406.314.5120Email: kwyn@ View original content to download multimedia: SOURCE BioLab Sciences Sign in to access your portfolio
